Aug 15 (Reuters) - Novo Nordisk said on
Friday the U.S. Food and Drug Administration had granted
accelerated approval for its weight-loss drug Wegovy to treat a
serious liver condition known as metabolic
dysfunction-associated steatohepatitis.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by
Sriraj Kalluvila)